The histone H2B ubiquitin ligase RNF40 is required for HER2-driven mammary tumorigenesis

The HER2-positive breast cancer subtype (HER2(+)-BC) displays a particularly aggressive behavior. Anti-HER2 therapies have significantly improved the survival of patients with HER2(+)-BC. However, a large number of patients become refractory to current targeted therapies, necessitating the developme...

Descripción completa

Detalles Bibliográficos
Autores principales: Wegwitz, Florian, Prokakis, Evangelos, Pejkovska, Anastasija, Kosinsky, Robyn Laura, Glatzel, Markus, Pantel, Klaus, Wikman, Harriet, Johnsen, Steven A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568723/
https://www.ncbi.nlm.nih.gov/pubmed/33070155
http://dx.doi.org/10.1038/s41419-020-03081-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568723/
https://www.ncbi.nlm.nih.gov/pubmed/33070155
http://dx.doi.org/10.1038/s41419-020-03081-w

Ejemplares similares